Obesity, non-alcoholic fatty liver disease, COVID-19: dangerous liaisons

The pandemic of COVID-19 is changing the usual clinical practice. Most of the drugs used for the etiotropic and pathogenetic therapy of COVID-19 do not have a sufficient evidence base, approaches to therapy of liver, gastrointestinal tract and other body systems damage in the structure of COVID-19 a...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: S. V. Tikhonov, V. D. Dekkanova, S. A. Vinnichuk, T. S. Fil, N. V. Bakulina
Médium: Artigo
Jazyk:Russo
Vydáno: Remedium Group LLC 2021-05-01
Edice:Медицинский совет
Témata:
obesity
abdominal obesity
covid-19
sars-cov-2
hepatitis
drug-induced hepatitis
non-alcoholic fatty liver disease
On-line přístup:https://www.med-sovet.pro/jour/article/view/6166
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky